- -

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

Mostrar el registro sencillo del ítem

Ficheros en el ítem

Thumbnail
Nombre: García-Foncillas; ...
Tamaño: 344.7Kb
Formato: PDF
Descripción: Versión editorial
Abrir
dc.contributor.author García-Foncillas, J. es_ES
dc.contributor.author Tabernero, J. es_ES
dc.contributor.author Ëlez, E. es_ES
dc.contributor.author Aranda, E. es_ES
dc.contributor.author Benavides, M. es_ES
dc.contributor.author Camps-Herrrero, Carlos es_ES
dc.contributor.author Jantus-Lewintre, Eloisa es_ES
dc.contributor.author Lopez, R. es_ES
dc.contributor.author Muinelo-Romay, L. es_ES
dc.contributor.author Montagut, C. es_ES
dc.contributor.author Antón, A. es_ES
dc.contributor.author Lopez, G. es_ES
dc.contributor.author Diaz-Rubio, E. es_ES
dc.contributor.author Rojo, F. es_ES
dc.contributor.author Vivancos, A. es_ES
dc.date.accessioned 2020-06-12T03:33:30Z
dc.date.available 2020-06-12T03:33:30Z
dc.date.issued 2018-12-11 es_ES
dc.identifier.issn 0007-0920 es_ES
dc.identifier.uri http://hdl.handle.net/10251/146168
dc.description.abstract [EN] BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented. METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient. RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689-0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease. CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy. es_ES
dc.description.sponsorship This work was supported by Sysmex Inostics, Inc as well as the AES Programme [Grant Numbers PI15/00934, PT17/0015/0006]. The funders had no involvement in the writing of this manuscript but did review for medical accuracy prior to submission. es_ES
dc.language Inglés es_ES
dc.publisher Nature Publishing Group es_ES
dc.relation.ispartof British Journal of Cancer es_ES
dc.rights Reconocimiento (by) es_ES
dc.subject Circulating tumor DNA es_ES
dc.subject Plus cetuximab treatment es_ES
dc.subject Growth-Factor receptor es_ES
dc.subject Anti-EGFR therapy es_ES
dc.subject Clinical-Relevance es_ES
dc.subject Digital PCR es_ES
dc.subject Kras es_ES
dc.subject Folfiri es_ES
dc.subject Braf es_ES
dc.subject Heterogeneity es_ES
dc.subject.classification BIOLOGIA CELULAR es_ES
dc.title Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1038/s41416-018-0293-5 es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//PI15%2F00934/ES/Papel de la heterogeneidad tumoral y la reprogramación dinámica de la célula tumoral en la resistencia a anticuerpos anti-HER2 en cáncer de mama HER2 positivo./ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/ISCIII//PT17%2F0015%2F0006/ es_ES
dc.rights.accessRights Abierto es_ES
dc.contributor.affiliation Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia es_ES
dc.description.bibliographicCitation García-Foncillas, J.; Tabernero, J.; Ëlez, E.; Aranda, E.; Benavides, M.; Camps-Herrrero, C.; Jantus-Lewintre, E.... (2018). Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. British Journal of Cancer. 119(12):1464-1470. https://doi.org/10.1038/s41416-018-0293-5 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion https://doi.org/10.1038/s41416-018-0293-5 es_ES
dc.description.upvformatpinicio 1464 es_ES
dc.description.upvformatpfin 1470 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 119 es_ES
dc.description.issue 12 es_ES
dc.identifier.pmid 30467411 es_ES
dc.identifier.pmcid PMC6288144 es_ES
dc.relation.pasarela S\388745 es_ES
dc.contributor.funder Sysmex Inostics, Inc. es_ES
dc.contributor.funder Ministerio de Economía y Competitividad es_ES
dc.description.references Malvezzi, M. et al. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann. Oncol. 28, 1117–1123 (2017). es_ES
dc.description.references Lockhart, A. C. & Berlin, J. D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol. 32, 52–60 (2005). es_ES
dc.description.references Di Fiore, F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 96, 1166–1169 (2007). es_ES
dc.description.references Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008). es_ES
dc.description.references Douillard, J.-Y. et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. New Engl. J. Med. 369, 1023–1034 (2013). es_ES
dc.description.references Bokemeyer, C. et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur. J. Cancer 51, 1243–1252 (2015). es_ES
dc.description.references Peeters, M. et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin. Cancer Res. 21, 5469–5479 (2015). es_ES
dc.description.references Van Cutsem, E. et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 33, 692–700 (2015). es_ES
dc.description.references Stintzing, S. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 17, 1426–1434 (2016). es_ES
dc.description.references Benson, A. B. et al. Colon cancer, version 3. 2014. J. Natl Compr. Cancer Netw. 12, 1028–1059 (2014). es_ES
dc.description.references Allegra C. J. et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti–epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J. Clin. Oncol. 34, 179–185 (2016). es_ES
dc.description.references Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016). es_ES
dc.description.references Garcia-Foncillas, J. et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann. Oncol. 28, 2943–2949 (2017). es_ES
dc.description.references Atreya, C. E., Corcoran, R. B. & Kopetz, S. Expanded RAS: refining the patient population. J. Clin. Oncol. 33, 682–685 (2015). es_ES
dc.description.references Jeong, K. Y., Kim, E. K., Park, M. H. & Kim, H. M. Perspective on cancer therapeutics utilizing analysis of circulating tumor cells. Diagnostics 8, E23 (2018). es_ES
dc.description.references Spindler, K. G. et al. Cell-free DNA in metastatic colorectal cancer: a systematic review and meta-analysis. Oncologist 22, 1049–1055 (2017). es_ES
dc.description.references Janku, F. et al. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann. Oncol. 28, 642–650 (2017). es_ES
dc.description.references Luthra, R., Chen, H., Roy-Chowdhuri, S. & Singh, R. R. Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges. Cancers 7, 2023–2036 (2015). es_ES
dc.description.references Denis, J. A., Guillerm, E., Coulet, F., Larsen, A. K. & Lacorte, J. M. The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing. Mol. Diagn. Ther. 21, 587–600 (2017). es_ES
dc.description.references Grasselli, J. et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann. Oncol. 28, 1294–1301 (2017). es_ES
dc.description.references Schmiegel, W. et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol. Oncol. 11, 208–219 (2017). es_ES
dc.description.references Vidal, J. et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann. Oncol. 28, 1325–1332 (2017). es_ES
dc.description.references Sorich, M. J. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of random, controlled trials. Ann. Oncol. 26, 13–21 (2015). es_ES
dc.description.references Baldus, S. E. et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 16, 790–799 (2010). es_ES
dc.description.references Watanabe, T. et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis. Colon Rectum 54, 1170–1178 (2011). es_ES
dc.description.references Artale, S. et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217–4219 (2008). es_ES
dc.description.references Kim, M. J. et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 12, 347 (2012). es_ES
dc.description.references Mostert, B. et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J. Cancer 133, 130–141 (2013). es_ES
dc.description.references Morelli, M. P. et al. Character the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731–736 (2015). es_ES
dc.description.references Laurent-Puig, P. et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 21, 1087–1097 (2015). es_ES
dc.description.references de Castro, D. G. et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br. J. Cancer 107, 345–351 (2012). es_ES
dc.description.references Azuara, D. et al. Nanofluidic digital PCR and extended genotyping of RAS and BRAF for improved selection of metastatic colorectal cancer patients for anti-EGFR therapies. Mol. Cancer Ther. 15, 1106–1112 (2016). es_ES
dc.description.references Tack, V. et al. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. Oncologist 20, 257–262 (2015). es_ES
dc.description.references Normanno, N. et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann. Oncol. 29, 112–118 (2018). es_ES
dc.description.references Thierry, A. R. et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann. Oncol. 28, 2149–2159 (2017). es_ES
dc.description.references Tie, J. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26, 1715–1722 (2015). es_ES
dc.description.references Garlan, F. et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL Study). Clin. Cancer Res. 23, 5416–5425 (2017). es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem